Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Asxl1 deficiency in embryonic fibroblasts leads to cellular senescence via impairment of the AKT-E2F pathway and Ezh2 inactivation.

Youn HS, Kim TY, Park UH, Moon ST, An SJ, Lee YK, Hwang JT, Kim EJ, Um SJ.

Sci Rep. 2017 Jul 12;7(1):5198. doi: 10.1038/s41598-017-05564-x.

2.

Long non-coding RNA LUCAT1 is associated with poor prognosis in human non-small lung cancer and regulates cell proliferation via epigenetically repressing p21 and p57 expression.

Sun Y, Jin SD, Zhu Q, Han L, Feng J, Lu XY, Wang W, Wang F, Guo RH.

Oncotarget. 2017 Apr 25;8(17):28297-28311. doi: 10.18632/oncotarget.16044.

3.

Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15.

Su J, Zhang E, Han L, Yin D, Liu Z, He X, Zhang Y, Lin F, Lin Q, Mao P, Mao W, Shen D.

Cell Death Dis. 2017 Mar 9;8(3):e2665. doi: 10.1038/cddis.2017.83.

4.

Visualizing Changes in Cdkn1c Expression Links Early-Life Adversity to Imprint Mis-regulation in Adults.

Van de Pette M, Abbas A, Feytout A, McNamara G, Bruno L, To WK, Dimond A, Sardini A, Webster Z, McGinty J, Paul EJ, Ungless MA, French PM, Withers DJ, Uren A, Ferguson-Smith AC, Merkenschlager M, John RM, Fisher AG.

Cell Rep. 2017 Jan 31;18(5):1090-1099. doi: 10.1016/j.celrep.2017.01.010.

5.

Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language.

Iguchi E, Safgren SL, Marks DL, Olson RL, Fernandez-Zapico ME.

Yale J Biol Med. 2016 Dec 23;89(4):575-590. eCollection 2016 Dec. Review.

6.

Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non-small-cell Lung Cancer by Binding to EZH2 and Suppressing p57.

Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ.

Mol Ther Nucleic Acids. 2016 Nov 15;5(11):e385. doi: 10.1038/mtna.2016.94.

7.

A cross-talk between DNA methylation and H3 lysine 9 dimethylation at the KvDMR1 region controls the induction of Cdkn1c in muscle cells.

Andresini O, Ciotti A, Rossi MN, Battistelli C, Carbone M, Maione R.

Epigenetics. 2016 Nov;11(11):791-803. Epub 2016 Sep 9.

PMID:
27611768
8.

GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.

Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, Li CW, Wei Y, Nie L, Yamaguchi H, Hung MC.

Oncotarget. 2016 Aug 30;7(35):57131-57144. doi: 10.18632/oncotarget.11008.

9.

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.

Mahara S, Lee PL, Feng M, Tergaonkar V, Chng WJ, Yu Q.

Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3735-44. doi: 10.1073/pnas.1602079113. Epub 2016 Jun 14.

10.

E2F1-induced upregulation of long noncoding RNA LINC00668 predicts a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically silencing of CKIs.

Zhang E, Yin D, Han L, He X, Si X, Chen W, Xia R, Xu T, Gu D, De W, Guo R, Xu Z, Chen J.

Oncotarget. 2016 Apr 26;7(17):23212-26. doi: 10.18632/oncotarget.6745.

11.

Increased expression of long noncoding RNA TUG1 predicts a poor prognosis of gastric cancer and regulates cell proliferation by epigenetically silencing of p57.

Zhang E, He X, Yin D, Han L, Qiu M, Xu T, Xia R, Xu L, Yin R, De W.

Cell Death Dis. 2016 Feb 25;7:e2109. doi: 10.1038/cddis.2015.356.

12.

Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.

Yeh CH, Bai XT, Moles R, Ratner L, Waldmann TA, Watanabe T, Nicot C.

Mol Cancer. 2016 Feb 16;15:15. doi: 10.1186/s12943-016-0500-z. Erratum in: Mol Cancer. 2016;15:20. Toshiki, Watanabe [Corrected to Watanabe, Toshiki].

13.

Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.

Song X, Gao T, Wang N, Feng Q, You X, Ye T, Lei Q, Zhu Y, Xiong M, Xia Y, Yang F, Shi Y, Wei Y, Zhang L, Yu L.

Sci Rep. 2016 Feb 12;6:20864. doi: 10.1038/srep20864.

14.

Targeting EZH2 in cancer.

Kim KH, Roberts CW.

Nat Med. 2016 Feb;22(2):128-34. doi: 10.1038/nm.4036. Review.

15.

Cbx4: A new guardian of p63's domain of epidermal control.

Cohen I, Ezhkova E.

J Cell Biol. 2016 Jan 4;212(1):9-11. doi: 10.1083/jcb.201512032. Epub 2015 Dec 28.

16.

Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.

Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II.

Cancer Res. 2016 Feb 1;76(3):675-85. doi: 10.1158/0008-5472.CAN-15-1141. Epub 2015 Dec 16.

17.

Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.

Dudakovic A, Camilleri ET, Xu F, Riester SM, McGee-Lawrence ME, Bradley EW, Paradise CR, Lewallen EA, Thaler R, Deyle DR, Larson AN, Lewallen DG, Dietz AB, Stein GS, Montecino MA, Westendorf JJ, van Wijnen AJ.

J Biol Chem. 2015 Nov 13;290(46):27604-17. doi: 10.1074/jbc.M115.672345. Epub 2015 Sep 30.

18.

Breast cancer risk and imprinting methylation in blood.

Harrison K, Hoad G, Scott P, Simpson L, Horgan GW, Smyth E, Heys SD, Haggarty P.

Clin Epigenetics. 2015 Sep 4;7:92. doi: 10.1186/s13148-015-0125-x. eCollection 2015.

19.

High Skp2/Low p57(Kip2) Expression is Associated with Poor Prognosis in Human Breast Carcinoma.

Yang C, Nan H, Ma J, Jiang L, Guo Q, Han L, Zhang Y, Nan K, Guo H.

Breast Cancer (Auckl). 2015 Aug 4;9(Suppl 1):13-21. doi: 10.4137/BCBCR.S30101. eCollection 2015.

20.

Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R.

Med Res Rev. 2015 Nov;35(6):1220-67. doi: 10.1002/med.21358. Epub 2015 Jul 30. Review.

Supplemental Content

Support Center